CRMD
CRMD clinical trials: CorMedix Inc.
Every trial on ClinicalTrials.gov where CorMedix Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 6
- Trials linked
- 6
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CRMD on the catalyst calendar · CRMD registry changes
- Primary completion Jan 2028Sponsor estimatePhase 3NCT06822426Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent...CorMedix Therapeutics · Central Line Associated Blood Stream Infections (CLABSI)RecruitingCRMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 4NCT06714864Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of AgeCorMedix Therapeutics · Catheter-Related InfectionsRecruitingCRMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06707480Expanded Access Program for Patients at Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical TrialsCorMedix Therapeutics · Catheter-related Bloodstream InfectionNo longer availableCRMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2018ActualPhase 3NCT02651428Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream InfectionCorMedix Therapeutics · Kidney Failure, ChronicCompletedCRMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2013Sponsor estimatePhase 3NCT01391520Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast AgentCorMedix Therapeutics · Acute Kidney InjuryWithdrawnCRMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2011ActualPhase 2NCT01146925Deferiprone for the Prevention of Contrast-Induced Acute Kidney InjuryCorMedix Therapeutics · Contrast-Induced Acute Kidney InjuryCompletedCRMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner